欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Angiogenesis > Sitravatinib

浏览历史

S82021

Sitravatinib

源叶(MedMol) 98%
  • 英文名:
  • Sitravatinib
  • 别名:
  • N-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N'1-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]met
  • CAS号:
  • 1123837-84-2
  • 分子式:
  • C33H29F2N5O4S
  • 分子量:
  • 629.6763
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S82021-5mg 98% ¥380.00元 >10 - - - EA 加入购物车
源叶(MedMol) S82021-10mg 98% ¥610.00元 >10 - - - EA 加入购物车
源叶(MedMol) S82021-50mg 98% ¥1910.00元 5 - - - EA 加入购物车
源叶(MedMol) S82021-100mg 98% ¥3000.00元 2 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment
  • 靶点: VEGFR3:2 nM (IC50);VEGFR1:6 nM (IC50);VEGFR2:5 nM (IC50);TrkA:5 nM (IC50);TrkB:9 nM (IC50);DDR1:29 nM (IC50);DDR2:0.5 nM (IC50);Axl:1.5 nM (IC50);MER:2 nM (IC50);FLT3:8 nM (IC50);KIT:6 nM (IC50);DiscoidinDomainReceptor(DDR); VEGFR; FLT; Trkreceptor; TAMReceptor; c-Kit; EphrinReceptor
  • 体外研究:
    Sitravatinib (0.01 nM-10 μM; 14 days) reduces colony formation in a dose-dependent manner in KLN205 and E0771 cell lines. Sitravatinib (0.001-10 μM; 5 days) inhibits tumor cell viability with IC50s of approximately 1 μM in KLN205, E0771 and CT1B-A5 cell lines. Cell Viability Assay Cell Line: KLN205, E0771, CT1B-A5 cells Concentration: 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 5 days Result: Inhibited KLN205, E0771, CT1B-A5 cells with IC50s of approximately 1 μM.
  • 体内研究:
    Sitravatinib (20 mg/kg; p.o.; once per day for 6 days) significantly inhibits tumor progression and induces tumor regression in C57BL/6 mice bearing CT1B-A5 cells model. Animal Model: 6-week-old C57BL/6 mice (bearing CT1B-A5 cells) Dosage: 20 mg/kg Administration: Oral administration; once per day for 6 days Result: Significantly inhibited tumor progression and induced tumor regression.
  • 参考文献:
    1. Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget, 2016 Jan 26;7(4):4093-109. 2. Du W, et al. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018 Nov 2;3(21). pii: 124184.
  • 溶解性: soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.588 ml 7.941 ml 15.881 ml
    5 mM 0.318 ml 1.588 ml 3.176 ml
    10 mM 0.159 ml 0.794 ml 1.588 ml
    50 mM 0.032 ml 0.159 ml 0.318 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。